Lv35
370 积分 2023-06-12 加入
P-123 Safety and clinical activity of belantamab mafodotin plus lenalidomide and dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma: the phase 1/2 BelaRd study
3小时前
已关闭
Carfilzomib, cyclophosphamide, and dexamethasone (KCd) for the treatment of triple-class relapsed/refractory multiple myeloma (RRMM)
1天前
已完结
BCMA-directed therapy for early relapsed and/or refractory multiple myeloma
7天前
已完结
Multiple myeloma
7天前
已完结
Disease Monitoring In Multiple Myeloma
8天前
已关闭
Approach to High-Risk Multiple Myeloma
8天前
已完结
Disease Monitoring In Multiple Myeloma
8天前
已关闭
Role of Consolidation and Maintenance
8天前
已关闭
P-242 Real-world treatment patterns and clinical outcomes amongst patients with relapsed/ refractory multiple myeloma previously treated with lenalidomide and an anti-CD38 monoclonal antibody
8天前
已关闭
COPD and Cardiovascular Disease
9天前
已完结
皖公网安备34019202002308
